Annual Statement of Changes in Beneficial Ownership (Form 5)

FORM 5 Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 3 Holdings Reported Form 4 Transactions Reported

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0362 Expires: January 31, 2005 Estimated average burden hours per response... 1.0

1. Name and Address of Reporting Person * Aminov Erez 2. Issuer Name and Ticker or Trading Symbol MIRA PHARMACEUTICALS, INC. [MIRA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) CEO and Chairman / (Last) (First) (Middle) C/O MIRA PHARMACEUTICALS, INC. , 1200 BRICKELL AVE. SUITE 1950 #1183 3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 2025-12-31 (Street) MIAMI FL 33131 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Join/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code 4. Securities Acquired (A) or Disposed of (D) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) 6. Ownership Form: Direct (D) or Indirect (I) 7. Nature of Indirect Beneficial Ownership Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code

5. Number of Derivative Securities Acquired (A) or Disposed of (D)

6. Date Exercisable and Expiration Date

7. Title and Amount of Securities Underlying Derivative Security

8. Price of Derivative Security

9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)

11. Nature of Indirect Beneficial Ownership

(A)

(D)

Date Exercisable

Expriation Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Aminov Erez C/O MIRA PHARMACEUTICALS, INC. 1200 BRICKELL AVE. SUITE 1950 #1183 MIAMI, FL33131	X		CEO and Chairman

Signatures

/s/ Erez Aminov		2026-02-17
**Signature of Reporting Person		Date

Explanation of Responses:

(*)	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**)	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4.
(2)	Represents grants of RSUs with underlying shares of Common Stock under the Issuer's 2024 Omnibus Equity Incentive Plan (the "Plan"), for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The RSUs hereunder vested upon issuance.
(3)	Represents exercise of 234,595 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on March 26, 2024, with 50% of such options vesting on the six-month anniversary date of the grant, and the remaining half vesting on the one-year anniversary date of the grant, pursuant to a grant under the Plan at an exercise price of $1.16 each.
(4)	Represents exercise of 379,000 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.84 each.
(5)	Represents grants of options with underlying shares of Common Stock under the Plan, for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The options hereunder vested upon issuance.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.